Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Accumulated Expenses of $488257.4 for Q4 2025, down 37.56% year-over-year from $781974.7 in Q4 2024, and down 7.7% quarter-over-quarter from $529000.0 in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Accumulated Expenses for 3 consecutive years, with $488257.4 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 37.56% year-over-year to $488257.4; the TTM figure through Dec 2025 stood at $488257.4 (down 37.56% YoY), while the FY2025 annual figure was $495000.0, down 35.63% from the prior year.
- Accumulated Expenses declined to $488257.4 in Q4 2025 per ZYBT's latest filing, from $529000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $781974.7 in Q4 2024 and bottomed at $400273.5 in Q4 2023.
- Historically, Accumulated Expenses has averaged $549876.4 across 3 years, with a median of $508628.7 in 2025.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 95.36% — and 2025, when it sank 37.56%.
- Zhengye Biotechnology Holding's Accumulated Expenses stood at $400273.5 in 2023, then soared by 95.36% to $781974.7 in 2024, then tumbled by 37.56% to $488257.4 in 2025.
- Business Quant data shows ZYBT's Accumulated Expenses at $488257.4 in Q4 2025, $529000.0 in Q2 2025, and $781974.7 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Zhengye Biotechnology Holding | 88.82 Mn | 81.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 488,257.38 |
| Jun 30, 2025 | 529,000.00 |
| Dec 31, 2024 | 781,974.70 |
| Dec 31, 2023 | 400,273.47 |